# Dupilumab

## Dupixent inj 300mg/2mL

| 藥物代碼 | IDUPI |
| :--- | :--- |
| 適應症 | Dupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adult patients who are candidates for systemic therapy. |
| 副作用 | &gt;10%: Local: Injection site reaction \(10% to 18%\)1% to 10%:Gastrointestinal: Oral herpes simplex infection \(4%\)Hematologic & oncologic: Eosinophilia \(&lt;2%\)Immunologic: Antibody development \(6% to 9%; neutralizing: 2% to 4%\)Infection: Herpes simplex infection \(2%\)Ophthalmic: Conjunctivitis \(10%\), eye pruritus \(1%\)Respiratory: Oropharyngeal pain \(2%\) |
| 禁忌 | Known hypersensitivity to dupilumab or any component of the formulation |
| 藥物保存方式 | 2-8 ℃ |
| 用法用量 | DUPIXENT is administered by subcutaneous injection. The recommended dose of DUPIXENT for adult patients is an initial dose of 600 mg \(two 300 mg injections\), followed by 300 mg given every other week. |
| 肝功能異常 | 無需調整劑量 |
| 腎功能異常 | 無需調整劑量 |
| 懷孕用藥危分級 | 尚未確立 |
| 孕期用藥建議 | N/A |
| 附帶說明 | N/A |
| 哺乳期用藥建議 | Unknown 尚未建立 |
| 附帶說明 | 1.若先施打Dupixent inj 300mg/2mL藥品，需間隔 12週才可施打活性疫苗。 2.若先施打活性疫苗，需間隔 2週，才可施打Dupixent inj 300mg/2mL。 |
| 注射劑給藥建議途徑 | SC |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | N/A |
| IVP 用法建議 | X |
| IVD 用法建議 | X |
| 注意事項 | Avoid use of live vaccines in patients treated with DUPIXENT. |

